Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 2
1904 1
1928 2
1939 1
1940 2
1943 1
1944 1
1945 2
1946 1
1947 4
1948 2
1949 6
1950 3
1951 8
1952 7
1953 5
1954 4
1955 10
1956 9
1957 12
1958 23
1959 13
1960 6
1961 6
1962 7
1963 12
1964 11
1965 23
1966 15
1967 17
1968 8
1969 12
1970 11
1971 12
1972 21
1973 28
1974 10
1975 17
1976 18
1977 25
1978 22
1979 18
1980 13
1981 15
1982 7
1983 14
1984 23
1985 19
1986 27
1987 20
1988 33
1989 32
1990 29
1991 39
1992 48
1993 36
1994 47
1995 56
1996 47
1997 49
1998 54
1999 64
2000 58
2001 82
2002 73
2003 109
2004 133
2005 180
2006 177
2007 192
2008 241
2009 249
2010 259
2011 330
2012 399
2013 389
2014 413
2015 487
2016 500
2017 495
2018 484
2019 507
2020 604
2021 652
2022 627
2023 612
2024 540
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

8,968 results

Results by year

Filters applied: . Clear all
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: banerjee s. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Precocious Puberty.
Banerjee S, Bajpai A. Banerjee S, et al. Indian J Pediatr. 2023 Jun;90(6):582-589. doi: 10.1007/s12098-023-04554-4. Epub 2023 Apr 19. Indian J Pediatr. 2023. PMID: 37074536 Review.
New therapies for clear cell ovarian carcinoma.
Stewart J, Cunningham N, Banerjee S. Stewart J, et al. Among authors: banerjee s. Int J Gynecol Cancer. 2023 Mar 6;33(3):385-393. doi: 10.1136/ijgc-2022-003704. Int J Gynecol Cancer. 2023. PMID: 36878571 Review.
Stricturing Crohn's Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions.
Mukherjee PK, Nguyen QT, Li J, Zhao S, Christensen SM, West GA, Chandra J, Gordon IO, Lin S, Wang J, Mao R, Czarnecki D, Rayan C, Goren I, Banerjee S, Kotak P, Plesec T, Lal S, Fabre T, Asano S, Bound K, Hart K, Park C, Martinez R, Dower K, Wynn TA, Hu S, Naydenov N, Decaris M, Turner S, Holubar SD, Steele SR, Fiocchi C, Ivanov AI, Kravarik KM, Rieder F. Mukherjee PK, et al. Among authors: banerjee s. Gastroenterology. 2023 Nov;165(5):1180-1196. doi: 10.1053/j.gastro.2023.07.014. Epub 2023 Jul 26. Gastroenterology. 2023. PMID: 37507073
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV. Oaknin A, et al. Among authors: banerjee s. Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915. Clin Cancer Res. 2023. PMID: 37363992 Free PMC article.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Pérez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A. Ledermann JA, et al. Among authors: banerjee s. Ann Oncol. 2024 Mar;35(3):248-266. doi: 10.1016/j.annonc.2023.11.015. Epub 2024 Feb 1. Ann Oncol. 2024. PMID: 38307807
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, Collins DC, Banerjee S, Mathews CA, Gennigens C, Cibula D, Tewari KS, Madsen K, Köse F, Jackson AL, Boere IA, Scambia G, Randall LM, Sadozye A, Baurain JF, Gort E, Zikán M, Denys HG, Ottevanger N, Forget F, Mondrup Andreassen C, Eaton L, Chisamore MJ, Viana Nicacio L, Soumaoro I, Monk BJ. Vergote I, et al. Among authors: banerjee s. J Clin Oncol. 2023 Dec 20;41(36):5536-5549. doi: 10.1200/JCO.23.00720. Epub 2023 Aug 31. J Clin Oncol. 2023. PMID: 37651655 Free PMC article. Clinical Trial.
8,968 results